What Is Glimepiride? Uses, Dose, and Risks
Glimepiride is an oral sulfonylurea for type 2 diabetes that boosts insulin release, lowering A1C by 1 to 2 points but risking hypoglycemia.
Why Am I Suddenly Hungry All the Time? Is It Perimenopause?
Sudden, constant hunger in your 40s or 50s is often tied to perimenopause-driven hormone shifts. Learn the biology, the red flags, and what the evidence actually supports.
Why Do Women Gain Weight During Menopause?
A clinically detailed explanation of why menopause causes weight gain, covering estrogen loss, metabolic slowdown, cortisol, sleep, and evidence-based treatments including HRT and GLP-1 agonists.
Why Visceral Fat Targets Your Heart After Menopause
After menopause, estrogen loss redirects fat storage into the abdomen, where it is linked to inflammation, insulin resistance, and cardiovascular risk. This article explains the mechanisms, distinguishes established evidence from areas needing verification, and outlines what a reader can realistically act on.
How Do Processed Foods Undermine Gut Health and Weight Regulation?
Processed foods disrupt gut microbiome diversity, trigger chronic low-grade inflammation, and hijack appetite-regulating hormones. Learn the specific mechanisms, the clinical evidence, and what dietary changes actually move the needle.
Is PCOS Genetic? What We Know About Family Risk
PCOS runs in families, but the inheritance pattern is complex. Learn what genetic research, twin studies, and candidate gene data tell us about your family risk and what to do about it.
What Are the Best Fiber Supplements for Women During Menopause?
A guide to the best fiber supplements for menopausal women, covering types, doses, clinical evidence, and how fiber affects blood sugar, weight, and cardiovascular risk during the menopause transition.
Does Cigna Cover Trulicity? Coverage Rules, Prior Auth, and Appeals Explained
A complete guide to Cigna coverage for Trulicity (dulaglutide), including formulary tier, prior authorization criteria, step therapy requirements, denial appeals, and manufacturer savings options.
Trulicity Overdose and Accidental Excess Dose: What to Do and Why It Happens
A guide to dulaglutide (Trulicity) overdose: symptoms, mechanisms, treatment protocols, and when to seek emergency care.
Avodart (Dutasteride) Safety for Adults Ages 30 to 49
A guide to dutasteride (Avodart) safety in adults aged 30, 49, covering sexual side effects, cardiovascular signals, cancer risk, drug interactions, and how to weigh risks against benefits for BPH and hair loss.
Avodart Appetite & Cravings Changes: What the Evidence Actually Shows
Does dutasteride (Avodart) change appetite or food cravings? A deep dive into the pharmacology, clinical trial data, and patient reports around dutasteride and appetite.
Avodart Cardiovascular Impact Long-Term: What the Evidence Actually Shows
A deep dive into dutasteride (Avodart) and long-term cardiovascular risk, covering the REDUCE trial, PCPT-era data, MACE signals, lipid effects, and current prescribing guidance for men on 5-alpha-reductase inhibitor therapy.
Does Cigna Cover Avodart (Dutasteride)? Coverage, PA, and Appeal Guide
Find out whether Cigna covers Avodart (dutasteride) for BPH and hair loss, what prior-authorization criteria apply, how step therapy works, and how to appeal a denial.
Avodart (Dutasteride) Geriatric Monitoring: What Every Clinician Needs to Know for Patients 65+
A clinical guide to dutasteride (Avodart) monitoring in adults 65 and older, covering falls risk, renal considerations, drug interactions, PSA interpretation, and deprescribing thresholds.
Avodart Mental Health and Mood Impact: What the Evidence Actually Shows
A deep dive into dutasteride (Avodart) and its effects on mood, depression, anxiety, libido, and cognitive function, with primary-literature citations and clinical guidance.
Avodart Muscle Preservation Strategies: What the Evidence Actually Shows
A clinician-level review of dutasteride (Avodart) and muscle preservation strategies, covering DHT suppression, resistance training protocols, protein targets, and monitoring guidance backed by primary-source evidence.
Avodart (Dutasteride) Monitoring for Older Adults Ages 50 to 64
A guide to dutasteride (Avodart) monitoring protocols for men and women aged 50 to 64, covering PSA interpretation, cardiovascular checks, hormone interactions, and safety labs at each follow-up visit.
Avodart Restarting After Acute Illness: A Clinical Guide to Dutasteride Interruptions
What happens when you stop dutasteride during illness, when it's safe to restart, and exactly how to resume therapy after acute illness. guidance with primary-literature citations.
Avodart Pre-Surgery Hold Window: How Long to Stop Dutasteride Before an Operation
Board-reviewed guide on the dutasteride (Avodart) pre-surgery hold window: when to stop, why it matters for PSA, bleeding, and anesthesia, and how to safely restart.
Avodart Dosing in Renal Impairment: What Clinicians and Patients Need to Know
A clinician-level review of dutasteride (Avodart) dosing in renal impairment, covering pharmacokinetics, mechanism of action, trial data, and practical prescribing guidance.
Avodart Sleep Architecture Impact: What Dutasteride Does to Your Sleep
A clinician-level review of how dutasteride (Avodart) affects sleep architecture, including neurosteroid suppression, REM disruption, and clinical management strategies backed by primary literature.
Switching To or From Dutasteride (Avodart): A Clinical Protocol Guide
Everything clinicians and patients need to know about switching between dutasteride, finasteride, and other 5-alpha-reductase inhibitors, with trial evidence, dosing protocols, and pharmacokinetic rationale.
Avodart Young Adult (18 to 29) Monitoring: What to Track, How Often, and Why
A guide to dutasteride (Avodart) monitoring for men aged 18 to 29, covering labs, fertility, sexual side effects, PSA interpretation, and when to stop treatment.
Avodart (Dutasteride) Safety for Young Adults Ages 18 to 29: What the Evidence Actually Shows
A guide to dutasteride safety in young adults ages 18, 29, covering sexual side effects, fertility, mental health signals, contraindications, and monitoring protocols with primary-source citations.
Jardiance Bone Health and Density Impact: What the Evidence Shows
Does Jardiance (empagliflozin) affect bone density or fracture risk? A review of the clinical trial data, mechanisms, and monitoring guidance for patients and prescribers.
Restarting Jardiance (Empagliflozin) After Acute Illness: A Clinical Guide
When and how to safely restart empagliflozin after illness, surgery, or hospitalization. Covers sick-day rules, DKA risk, renal thresholds, and a step-by-step restart protocol backed by primary literature.
Enclomiphene Citrate Appetite & Cravings Changes: What the Evidence Shows
Does enclomiphene citrate change appetite or cravings? A clinician-level review of the mechanisms, clinical trial data, and practical guidance for men on enclomiphene therapy.
Enclomiphene Citrate Cancer Risk Signal Review
A physician-level review of the cancer risk signals associated with enclomiphene citrate, covering estrogen receptor pharmacology, published trial safety data, and how clinicians should counsel patients on off-label use for secondary hypogonadism.
Enclomiphene Citrate Geriatric (65+) Dosing: What Older Men Need to Know
A guide to enclomiphene citrate dosing in men aged 65 and older, covering starting doses, titration, renal and hepatic adjustments, fall risk, drug interactions, and monitoring protocols for secondary hypogonadism.
Enclomiphene Citrate: Metabolism and Energy Expenditure
A deep dive into how enclomiphene citrate affects testosterone, metabolic rate, body composition, and energy expenditure, with primary-literature citations and clinical dosing guidance.
Enclomiphene Citrate: Restarting After Acute Illness
A physician-level guide to safely restarting enclomiphene citrate after acute illness, covering when to pause, how to re-titrate, and what lab values guide the decision.
Enclomiphene Citrate and Sleep Architecture: What the Evidence Shows
A deep dive into how enclomiphene citrate affects sleep architecture, REM sleep, slow-wave sleep, and testosterone-driven circadian signaling in men with secondary hypogonadism.
Epitalon Cardiovascular Impact Long-Term: What the Evidence Actually Shows
A physician-level review of epitalon tetrapeptide's long-term cardiovascular effects, covering telomerase biology, oxidative stress, lipid profiles, and what Russian cohort data and preclinical trials reveal about heart health outcomes.
Epitalon Safety for Adults Ages 50 to 64: What the Evidence Actually Shows
A safety guide for epitalon tetrapeptide use in adults aged 50 to 64, covering current evidence, contraindications, drug interactions, and monitoring recommendations.
Epitalon Sleep Architecture Impact: What the Clinical Evidence Shows
A deep dive into how the tetrapeptide Epitalon affects sleep architecture, melatonin secretion, circadian rhythm regulation, and sleep quality in aging adults, with primary-literature citations throughout.
Epitalon: Switching From and To Other Drugs in Class
A clinician-level guide to switching protocols for epitalon tetrapeptide, covering mechanism, class comparisons, dosing cycles, and evidence-based transition strategies with primary-source citations.
Epitalon Young Adult (18-29) Monitoring: What Labs, Schedules, and Safety Checks You Actually Need
A complete clinical monitoring guide for adults aged 18-29 using epitalon tetrapeptide, covering baseline labs, cycle tracking, fertility considerations, and safety checkpoints backed by primary research.
Epitalon Safety for Young Adults (Ages 18 to 29): What You Need to Know
A clinical review of epitalon tetrapeptide safety in adults aged 18, 29, covering telomere biology, known risks, dosing considerations, fertility implications, and what current evidence does and does not support.
Oral Estradiol Cancer Risk Signal Review: What the Evidence Actually Shows
A review of oral estradiol cancer risk signals across breast, endometrial, ovarian, and other cancers, distinguishing WHI trial data from guideline statements and noting where citation verification is still required.
Oral Estradiol Safety in Adults 65 and Older: A Clinical Guide
A guide to oral estradiol safety in geriatric patients (65+), covering cardiovascular risk, VTE, breast cancer data, drug interactions, and deprescribing thresholds.
Oral Estradiol Missed-Dose Protocol: What to Do and Why It Matters
A guide to oral estradiol missed-dose management, covering pharmacokinetics, step-by-step recovery instructions, symptom implications, and the clinical evidence behind current recommendations.
Oral Estradiol Plateau and Non-Response Troubleshooting
A clinician-level guide to diagnosing and correcting oral estradiol plateau and non-response in menopausal HRT, covering pharmacokinetics, lab interpretation, dose adjustments, and route-switching strategies with primary literature citations.
Oral Estradiol Pre-Surgery Hold Window: When to Stop and When to Restart
A clinician-level guide to the oral estradiol pre-surgery hold window: timing, thrombotic risk mechanisms, guideline recommendations, and safe restart protocols after surgery.
Oral Estradiol and Sexual Function: What the Evidence Actually Shows
A deep dive into how oral estradiol affects libido, arousal, lubrication, and pain during sex, with primary-literature citations, real doses, and a clinical decision framework.
Oral Estradiol and Sleep Architecture: What the Clinical Evidence Shows
A clinician-level review of how oral estradiol affects sleep architecture, REM duration, slow-wave sleep, and sleep efficiency in menopausal women, with primary-literature citations and dosing context.
Does TRICARE Cover Oral Estradiol?
A complete guide to TRICARE coverage, formulary tier, prior authorization, step therapy, and appeal pathways for oral estradiol (estrace, generic 17-beta estradiol) for menopausal vasomotor symptoms.
Oral Estradiol Hair and Skin Changes: What the Evidence Actually Shows
A clinician-level review of how oral estradiol affects hair growth, hair loss, skin thickness, collagen, sebum, and wound healing, with primary-literature citations and practical dosing context.
Estradiol Patch Safety for Adults Ages 30 to 49
A guide to estradiol transdermal patch safety for adults aged 30 to 49, covering cardiovascular risk, breast cancer data, clot risk, contraindications, and monitoring protocols.
Estradiol Patch Autoimmune Disease Considerations
A clinician-level review of estradiol transdermal patch use in patients with autoimmune conditions, covering disease-specific risks, benefits, dosing, and monitoring protocols backed by primary literature.
Estradiol Patch Cardiovascular Impact Long-Term: What the Evidence Actually Shows
What long-term transdermal estradiol use appears to do to cardiovascular risk, how that differs from oral estrogen data, and where the evidence for the patch specifically is still incomplete.
Estradiol Patch Cognitive Function Impact: What the Evidence Actually Shows
A clinician-level review of how transdermal estradiol affects memory, processing speed, and dementia risk in peri- and postmenopausal women, framed around what is established, what is plausible, and what remains unproven.
Estradiol Patch: Compounded vs Branded Comparison
A clinician-level comparison of compounded and FDA-approved branded estradiol transdermal patches covering bioequivalence, safety data, regulatory status, cost, and how to choose the right formulation for menopausal hormone therapy.
Estradiol Patch Dosing for Adults Ages 50 to 64
Evidence-based guide to estradiol transdermal patch dosing for adults ages 50 to 64, including starting doses, titration schedules, cardiovascular risk stratification, and monitoring protocols prepared by the HealthRX.com Editorial Team.
Estradiol Patch Pharmacokinetics (ADME): How Transdermal Estradiol Is Absorbed, Distributed, Metabolized, and Excreted
A clinician-level review of estradiol patch pharmacokinetics covering absorption, distribution, metabolism, and excretion, with cited trial data, dose-exposure relationships, and practical prescribing implications.
Estradiol Patch Seasonal Use Considerations
A clinician-level guide to how heat, cold, humidity, and UV exposure affect estradiol transdermal patch adhesion, absorption, and dosing across seasons. Includes primary-literature citations, dosing guidance, and storage recommendations.
Does UnitedHealthcare Cover Estradiol Patch?
A detailed guide to UnitedHealthcare coverage for estradiol transdermal patches, including formulary tiers, prior authorization criteria, step therapy requirements, and how to appeal a denial.
Estradiol Patch Dosing for Young Adults (Ages 18 to 29)
A guide to estradiol transdermal patch dosing for women aged 18 to 29, covering starting doses, titration, the evidence base for this age group, and how patch therapy interacts with fertility and family planning goals.
Lunesta Cardiovascular Impact Long-Term: What the Evidence Actually Shows
A clinician-level review of eszopiclone's long-term cardiovascular effects, covering autonomic modulation, blood pressure data, arrhythmia risk, and what prescribers should monitor in patients taking Lunesta chronically.
Lunesta Cost vs. Alternatives: Eszopiclone Compared to Every Insomnia Drug in Class
A clinician-level breakdown of eszopiclone (Lunesta) cost, mechanism, and head-to-head comparison with zolpidem, zaleplon, benzodiazepines, doxepin, ramelteon, suvorexant, and lemborexant. Evidence-cited. Dosing tables included.
Lunesta Complete Drug-Drug Interaction Profile (Eszopiclone)
A citation-dense guide to every clinically significant drug-drug interaction with eszopiclone (Lunesta): CYP3A4 inhibitors, CNS depressants, opioids, antifungals, and more, with specific pharmacokinetic data and management recommendations.